Zai Lab Limited

Hello ladies and gentlemen, thank you for standing by and welcome to Xilab's second quarter 2021 financial results conference call. At this time, all participants are in a listen-only mode. Later, we will conduct a question and answer session and instructions will follow at that time. As a reminder, today's call is being recorded. It is now my pleasure to turn the floor over to Billy Cho, Chief Financial Officer of Xilab, who will make introductory comments.

Thank you, operator. Good morning and welcome, everyone. After the market closed yesterday, Dialab issued a press release providing the details of the company's financial results for the second quarter and the June 30th to 2021, as well as product highlights and corporate updates. The press release is available in the investor relations section of the company's corporate website at ir.dialaboratory.com. Today's call will be led by Dr. Samantha Duke, Dialab's founder, chairperson, and chief executive officer. She'll be joined by Tao Fu, Chief Strategy Officer, who will provide more details on her product portfolio along with the pipeline and commercial progress. I will conclude with comments on our financial results in the quarter. Dr. Alan Sandler, President, Head of Global Development Oncology, Dr. Harold Weinhart, Chief Medical Officer for Autoimmune and Infectious Diseases, and Jonathan Wong, Head of Business Development, will also be available to answer questions during the Q&A portions of the call. As a reminder for today's call, YLAB will be making certain forward-looking statements within the meaning of the Private Securities Mitigation Reform Act of 1995, including our business plans and objectives, and timing and success of our clinical trials, regulatory applications, and commercial launches. These forward-looking statements are not guarantees of future performance, and therefore we should not put undue reliance upon them. These statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from what we expect. I refer you to our SEC filing for a discussion of risk factors that could cause our actual results to differ materially from those discussed today. At this time, it is my pleasure to turn the call over to StyleLab founder, chairperson, and chief executive officer, Dr. Samantha Dew.

Thank you, Billy. Hello, everyone, and thank you all for joining us. On this call, I'll discuss highlights from our second quarter and provide the latest updates of what we expect to accomplish for the remainder of Kindi 21. Consistent with our top-track record, satellites continue to execute with speed and quality across our organization during the second quarter. We successfully launched King Lock in China in record time. King Lock is our third commercial product in oncology to launch over the last 16 months. and the first product in what we expect to become a world-class gadget concept franchise. We continue to generate strong revenue growth from our first two products, as well as an option. We entered into three strategic collaborations with Merati, Microgenics, and Schrodinger, respectively. to further strengthen and strengthen our disease area strongholds and our global pipeline. Tao and Billy will discuss this achievement in more detail. We now have 25 globally generated assets in our pipeline, and the quality, depth, and breadth of our pipeline will continue to grow. Notably, Tao products are in late phase development, of which five have already been approved in the U.S., and three have received FDA breakthrough therapy designation. In addition, our growing pipeline now includes 11 study-based programs with worldwide rights, including three in global clinical trials. We have used a broad, innovative, validated portfolio whose success will allow us to achieve significant scale within just three years. We will continue to leverage our scale and operating excellence to expand our pipeline with globally innovative products through strategic partnerships and internal R&D. We expect to achieve many exciting milestones across our product pipeline throughout the remainder of 2021. We expect approval of our third commercial product in Zara, a community-acquired bacterial pneumonia, and approved bacterial skin and skin structure infections by the NMPA. We also continue to make progress on additional registry filings and activities, We expect to have a discussion with the NNPA on the filing strategy for S. ticumab in the near future. We anticipate numerous data results during the rest of this year for Kinglock in second lung disease, for M. ticumab in gastric cancer, for CLN081 in non-small cell lung cancer, for PPX-0022 in non-small cells and gastric cancer, and for other product candidates in our global pipeline. We continue to invest in our worldwide organization and facilities. In September, we will expand our presence in the U.S. and firmly open a clinical development and business facility in Cambridge, Massachusetts. to tap into the Boston area bell farmer ecosystem. In the meantime, our existing R&D and business center in the San Francisco Bay Area and in China will continue to grow. That life has grown substantially since our inception seven years ago. And with the abundance of growth opportunities we see, we strongly believe that we feel in the early stage of our growth trajectory. And given the current breadth and depth of our portfolio, we have decided to hold an R&D day on September 22nd to take a deep dive into our pipeline and deep-dive its run source and to highlight the fundamental growth potential drive. We hope you come away from it with a more comprehensive understanding of what we are doing and what we expect to accomplish in the future. We believe we have a once-in-a-generation opportunity to build a leading global biopharmaceutical company with a strong foundation in both China and in the U.S. Tsai has been in a great position to capture growth opportunities with our global infrastructure and ever-growing first and our back-and-closet portfolio. We remain as committed as ever to our mission to develop innovative medicines addressing the underlying medical needs of patients around the world. We believe by doing this, we'll benefit our shareholders as well. With that, I'll now ask Paul to discuss our performance and perspective in more detail. Paul?